قالب وردپرس درنا توس
Home / Business / Seres Therapeutics Stock Scales Nasdaq Scales on Positive Data on Drugs

Seres Therapeutics Stock Scales Nasdaq Scales on Positive Data on Drugs



7;s rise is the company’s main drug, SER-109, that achieved the primary goal in a late-stage study in patients infected with Clostridium difficile (CDI) infections. CDI is currently the leading cause of hospital acquired infections in the US

Analysts were optimistic about the MCRB, which currently leads 508.1% for the year. Four out of five analysts in the coverage showed a “strong buy”, with one remaining at a quiet “hold” level. Meanwhile, the 12-month consensus price target of $ 8.08 is currently at a 61.2% discount from current levels.

The short sellers, meanwhile, have firmly taken control. Short-term interest rate increased 9.4% in the last two reporting periods and currently, 7.67 million short-sold shares account for 17.7% of outstanding shares. In other words, it would take almost twelve days to reach the average trading speed of Seres Therapeutics shares. If some of this pessimism starts to subside, it could bring some additional headwind to equity.

In option pits, traders were quick to jump in, with 28,000 calls and 49,000 placed on ice until today – 21 times the average of the day, with volume running at the highest percentage in annual range. The most popular are the orders of 7.50 August and calls on 5 October, with positions opened previously.

Despite only volume, today’s ordering trend is slightly different from recent activity. In the past 10 days, 5,547 calls and 4,930 orders have been exchanged, equivalent to a volume / order ratio of 1.13 at the Stock Exchange (ISE), Cboe Options Exchange (CBOE) and NASDAQ OMX PHLX (PHLX).


Source link